Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations tha...

Descripción completa

Detalles Bibliográficos
Autores: Gonzalez Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer Palter, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera Álvarez, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, 1953-, Martínez Picado, Francisco Javier, Cerezuela, Pablo, Soria, Ainara, Marquez, Ivan, Mandala, Mario, Berrocal, Alfonso, Spanish Melanoma Group (GEM).
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/176933
Acceso en línea:https://hdl.handle.net/2445/176933
Access Level:acceso abierto
Palabra clave:Melanoma
Immunoteràpia
Càncer
Immunotheraphy
Cancer
id ES_8c570fbddf18f7f1df83ee7f32a4dacb
oai_identifier_str oai:recercat.cat:2445/176933
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Gonzalez Cao, MariaPuertolas, TeresaRiveiro, MarMuñoz Couselo, EvaOrtiz, CarolinaParedes, RogerPodzamczer Palter, DanielManzano, Jose LuisMolto, JoseRevollo, BorisCarrera Álvarez, CristinaMateu, LourdesFancelli, SaraEspinosa, EnriqueClotet, Bonaventura, 1953-Martínez Picado, Francisco JavierCerezuela, PabloSoria, AinaraMarquez, IvanMandala, MarioBerrocal, AlfonsoSpanish Melanoma Group (GEM).MelanomaImmunoteràpiaCàncerMelanomaImmunotheraphyCancerCancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.BMJ Publishing Group2021202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/176933Articles publicats en revistes (Medicina)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1136/jitc-2020-001664Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 3, p. e001664https://doi.org/10.1136/jitc-2020-001664cc-by-nc (c) Gonzalez Cao, Maria et al., 2021http://creativecommons.org/licenses/by-nc/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1769332026-05-29T05:05:01Z
dc.title.none.fl_str_mv Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
spellingShingle Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Gonzalez Cao, Maria
Melanoma
Immunoteràpia
Càncer
Melanoma
Immunotheraphy
Cancer
title_short Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_full Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_fullStr Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_full_unstemmed Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_sort Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
dc.creator.none.fl_str_mv Gonzalez Cao, Maria
Puertolas, Teresa
Riveiro, Mar
Muñoz Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer Palter, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera Álvarez, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet, Bonaventura, 1953-
Martínez Picado, Francisco Javier
Cerezuela, Pablo
Soria, Ainara
Marquez, Ivan
Mandala, Mario
Berrocal, Alfonso
Spanish Melanoma Group (GEM).
author Gonzalez Cao, Maria
author_facet Gonzalez Cao, Maria
Puertolas, Teresa
Riveiro, Mar
Muñoz Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer Palter, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera Álvarez, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet, Bonaventura, 1953-
Martínez Picado, Francisco Javier
Cerezuela, Pablo
Soria, Ainara
Marquez, Ivan
Mandala, Mario
Berrocal, Alfonso
Spanish Melanoma Group (GEM).
author_role author
author2 Puertolas, Teresa
Riveiro, Mar
Muñoz Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer Palter, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera Álvarez, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet, Bonaventura, 1953-
Martínez Picado, Francisco Javier
Cerezuela, Pablo
Soria, Ainara
Marquez, Ivan
Mandala, Mario
Berrocal, Alfonso
Spanish Melanoma Group (GEM).
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Melanoma
Immunoteràpia
Càncer
Melanoma
Immunotheraphy
Cancer
topic Melanoma
Immunoteràpia
Càncer
Melanoma
Immunotheraphy
Cancer
description Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/176933
url https://hdl.handle.net/2445/176933
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1136/jitc-2020-001664
Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 3, p. e001664
https://doi.org/10.1136/jitc-2020-001664
dc.rights.none.fl_str_mv cc-by-nc (c) Gonzalez Cao, Maria et al., 2021
http://creativecommons.org/licenses/by-nc/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc (c) Gonzalez Cao, Maria et al., 2021
http://creativecommons.org/licenses/by-nc/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412910284931072
score 15,198674

Similares en LA Referencia